| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA1809037
Max Phase: Preclinical
Molecular Formula: C31H34N4O4
Molecular Weight: 526.64
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(C)OC(=O)Cn1cc2c3c(cccc31)C1=C[C@@H](C(=O)N3CCCC3)CN(C(=O)Nc3ccccc3)[C@@H]1C2
Standard InChI: InChI=1S/C31H34N4O4/c1-20(2)39-28(36)19-34-17-21-16-27-25(24-11-8-12-26(34)29(21)24)15-22(30(37)33-13-6-7-14-33)18-35(27)31(38)32-23-9-4-3-5-10-23/h3-5,8-12,15,17,20,22,27H,6-7,13-14,16,18-19H2,1-2H3,(H,32,38)/t22-,27-/m1/s1
Standard InChI Key: RNXRZAYVPFEIRJ-AJTFRIOCSA-N
Associated Targets(Human)
C-X-C chemokine receptor type 3 2736 Activities
Associated Targets(non-human)
C-X-C chemokine receptor type 3 96 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
C-X-C chemokine receptor type 3 21 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 526.64 | Molecular Weight (Monoisotopic): 526.2580 | AlogP: 4.69 | #Rotatable Bonds: 5 |
| Polar Surface Area: 83.88 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 13.36 | CX Basic pKa: | CX LogP: 3.73 | CX LogD: 3.73 |
| Aromatic Rings: 3 | Heavy Atoms: 39 | QED Weighted: 0.49 | Np Likeness Score: -0.67 |
References
| 1. Thoma G, Baenteli R, Lewis I, Jones D, Kovarik J, Streiff MB, Zerwes HG.. (2011) Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood., 21 (16): [PMID:21764306] [10.1016/j.bmcl.2011.06.070] |
Source
Source(1):